1. Home
  2. NIU vs DYN Comparison

NIU vs DYN Comparison

Compare NIU & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Niu Technologies

NIU

Niu Technologies

HOLD

Current Price

$3.45

Market Cap

275.6M

ML Signal

HOLD

DYN

Dyne Therapeutics Inc.

HOLD

Current Price

$15.60

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NIU
DYN
Founded
2014
1984
Country
China
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
275.6M
2.8B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
NIU
DYN
Price
$3.45
$15.60
Analyst Decision
Strong Buy
Analyst Count
0
17
Target Price
N/A
$39.94
AVG Volume (30 Days)
462.5K
1.9M
Earning Date
03-16-2026
02-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$625,182,280.00
N/A
Revenue This Year
$42.51
N/A
Revenue Next Year
$17.33
N/A
P/E Ratio
N/A
N/A
Revenue Growth
50.99
N/A
52 Week Low
$2.11
$6.36
52 Week High
$5.67
$25.00

Technical Indicators

Market Signals
Indicator
NIU
DYN
Relative Strength Index (RSI) 54.14 37.26
Support Level $3.36 $15.80
Resistance Level $3.58 $17.45
Average True Range (ATR) 0.19 0.99
MACD 0.03 -0.14
Stochastic Oscillator 56.15 6.93

Price Performance

Historical Comparison
NIU
DYN

About NIU Niu Technologies

Niu Technologies designs, manufactures and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycle, mopeds and bicycle series, including the NQi, MQi, UQi, F series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.

About DYN Dyne Therapeutics Inc.

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Share on Social Networks: